Evercore ISI cuts W.R. Berkley stock price target on growth concerns

Evercore ISI cut W.R. Berkley’s price target to $67 from $69 and kept an Underperform rating, citing limited confidence in growth acceleration and a low-single-digit net premiums written growth outlook that looks inconsistent with the stock’s ~15x P/E. The firm highlighted a better-than-expected quarter driven by an underwriting loss ratio beat and stronger buybacks, but also trimmed estimates by 1% on lower reinsurance growth and net investment income. Separately, W.R. Berkley’s Q1 2026 EPS came in at $1.30 vs. $1.14 expected and revenue at $3.69B vs. $3.18B, prompting Mizuho to raise its target to $68 from $66.

Analysis

The key issue is not the quarter but the durability of the underwriting cycle versus capital return support. WRB is being valued like a compounding specialty insurer, yet the market is getting evidence that top-line growth remains too modest to justify multiple expansion unless pricing and reserve tailwinds re-accelerate. That puts the stock in a narrow corridor where incremental buybacks help EPS optics, but they do little to solve the core problem of subscale growth translating into a mediocre forward return profile.

Second-order, lower reinsurance growth matters more than it sounds because it removes one of the few channels that can extend earnings momentum without taking incremental reserve risk. If reinsurance fades while casualty reserves remain a constraint, management is forced to choose between defending margin and chasing premium growth; either path can disappoint on one of the two key variables the market is underwriting. That makes the setup vulnerable to any deceleration in rate realization over the next 1-2 quarters, especially if peers continue to show better premium conversion.

The contrarian angle is that the estimate cuts may already be absorbing a lot of the bad news, while the company’s capital returns can keep downside contained in the near term. The market is likely discounting a slow-growth compounder rather than a deterioration story, so a sharp multiple compression would probably require either reserve noise or a visible drop in pricing discipline. Absent that, the stock may grind rather than break, but upside should remain capped unless management can prove that growth is inflecting faster than the current low-single-digit trajectory.

Key Decisions for Investors

• Stay underweight WRB into the next 1-2 quarters; the risk/reward is poor if growth stays low-single-digit while the multiple remains in the mid-teens.
• If owning the sector, prefer a pair trade: long a faster-growing specialty carrier versus short WRB for 1-3 months, targeting relative multiple re-rating as the market penalizes slower premium conversion.
• Sell out-of-the-money WRB calls against any existing long position for the next earnings cycle; the buyback floor supports the stock, but upside looks limited without a growth inflection.
• Use any post-earnings strength above the low- to mid-$60s to reduce exposure; the thesis breaks only if net premiums written accelerates for multiple quarters, which currently looks unlikely.